The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

IXCHIQ ® - Valneva 3 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ ® - Valneva 4 Valneva Receives Marketing Authorization in the UK for the World ...

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency (ANVISA) for its single-dose chikungunya vaccine, Ixchiq, for individuals aged 18 years and above.

IXCHIQ ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. It is approved in the U.S. 3, Europe 4, Canada 5 and the UK for the ...

EMA has maintained current recommendations for IXCHIQ ® for people from 12 to 64 years of age. The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee ...

including an important presentation on the Company´s vaccine IXCHIQ ®, the world’s first licensed chikungunya vaccine. The Company will have a display in the exhibit area of the congress at booth #424 ...

ACIP maintained its current recommendation for IXCHIQ ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered ...

IXCHIQ® - Valneva6 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® - Valneva7 Valneva Receives Marketing Authorization in the UK for the World’s ...